Wyeth

The General Hospital Corporation

American Cyanamid Company

Wyeth Holdings Corporation

Sridhar Krishna Rabindran

Allan Wissner

Daniel Arie Haber

Hwei-Ru Tsou

Haiyin He

Raffaella Sordella

Jeffrey E Settleman

James J Gibbons, Jr

Daphne Winifred Bell

Lee Greenberger

Nadia G Godin-Heymann

Eunice L Kwak

Charles Zacharchuk

Laurence Moore

A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described.

Antineoplastic combinations with mTOR inhibitor, trastuzumab and/or HKI-272

The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.

Method for treating gefitinib resistant cancer

The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB 569, HKI-272 and HKI-357.

This invention provides compounds of formula 1, having the structure wherein R, R, R, R, and Rare described within the specification.

Protein tyrosine kinase enzyme inhibitors

This invention provides the use of a combination of CCI-779 and EKB-569 in the treatment of neoplasms.

Treatment of neoplasms with CCI-779/EKB-569 combination

The present invention describes the use of fumitremorgin A, B and C and a series of diketopiperazines of Formula (I) to resensitize multidrug resistant (MDR) cancer cells to the cytotoxic effects of chemotherapeutic drugs.

Reversal of multidrug resistance in human colon carcinoma cells

Antineoplastic combinations comprising

Growing community of inventors

Chestnut Ridge, NY, United States of America

Sridhar Krishna Rabindran